ArticleBMC gastroenterology2025
Preoperative albumin-bilirubin grade combined with sarcopenia predicts long-term outcomes after laparoscopic gastrectomy for advanced gastric cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modified albumin-bilirubin grade predicts overall and progression-free survival in metastatic gastric cancer.Biomolecules & biomedicine · 2026Article
- Development and validation of a prognostic nutritional-inflammatory-immune score and web-based dynamic nomogram for gastric cancer following radical gastrectomy: a multicenter study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis retrospective study evaluated the predictive value of preoperative albumin–bilirubin (ALBI) grade combined with sarcopenia for the long-term prognosis of patients with advanced gastric cancer (AGC) undergoing laparoscopic radical surgery.
methodsThis study analyzed clinical and pathological data from 731 patients who underwent laparoscopic gastrectomy for AGC in 2011–2019. The training and validation datasets comprised 538 and 193 cases, respectively. Preoperative serum albumin and bilirubin levels were measured to calculate the ALBI score. Sarcopenia was evaluated using the Skeletal Muscle Index (SMI) calculated from preoperative computed tomography images. A new predictive index, s-ALBI, was then established by fitting ALBI and SMI. s-ALBI-1 was defined as low ALBI with no sarcopenia, s-ALBI-2 as low ALBI with sarcopenia or high ALBI with no sarcopenia, and s-ALBI-3 as high ALBI with sarcopenia. Kaplan-Meier survival analysis was used to compare the overall survival (OS) and recurrence-free survival (RFS) of patients in different groups. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors. The predictive ability was assessed using receiver operating characteristic curves and the area under the curve (AUC), followed by external validation.
resultsThe 5-year OS and RFS differed significantly between s-ALBI groups (OS: s-ALBI-1 vs. s-ALBI-2 vs. s-ALBI-3: 77.1% vs. 45.0% vs. 28.4%; RFS: s-ALBI-1 vs. s-ALBI-2 vs. s-ALBI-3: 67.9% vs. 38.5% vs. 24.8%, all P < 0.0001). Moreover, s-ALBI was an independent risk factor for the long-term prognosis of patients with AGC, with modest predictive performance for 5-year OS (AUC = 0.672) and RFS (AUC = 0.648). These results were further confirmed in the external validation set.
conclusionss-ALBI demonstrated modest predictive performance for long-term prognosis in patients with AGC undergoing laparoscopic gastrectomy. Preoperative risk stratification using s-ALBI may help guide personalized treatment plans and optimize therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.